Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Avon Products, Inc.    AVP

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Avon Names Johnson & Johnson Executive McCoy As CEO

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/09/2012 | 04:01pm CEST

--Avon taps Johnson & Johnson veteran Sherilyn McCoy as next CEO

--McCoy to replace Andrea Jung, who remains as executive chairman

--Appointment comes as struggling Avon defends itself against buyout bid

(Rewrites 1st paragraph and adds analyst comment.)

 
   By Paul Ziobro and Peter Loftus 
   Of  
 

Avon Products Inc. (>> Avon Products, Inc.) tapped Johnson & Johnson (JNJ) veteran Sherilyn S. McCoy as its next chief executive to steer the company through a turnaround and navigate a buyout bid from a smaller but determined rival.

The selection of McCoy, a highly regarded executive who was a candidate for the top spot at the health-care giant, is seen as a strong sign that Avon and embattled CEO Andrea Jung continue to dig in their heels against the $10 billion buyout disclosed last week by the fragrance giant Coty Inc.

"This is likely a clear sign that [Avon's] Board (and Ms. Jung) is actively resisting Coty's acquisition offier," Bernstein analyst Ali Dibadj said in a note Monday.

The New York consumer products company is turning to McCoy to succeed Jung, who will remain as executive chairman once McCoy takes over as CEO on April 23.

Avon has faced deep investor dissatisfaction over the past year as it failed to deal quickly with poor results in important overseas markets as well as a messy federal probe into allegations of bribery of officials overseas. Jung agreed to step down from the top job in December following an investor outcry over the company's poor financial results.

"Given her consistent record of outperforming against new challenges, we have great confidence that under Sheri's leadership, Avon can successfully execute against out long-term prospects," said Fred Hassan, lead director of Avon's board.

McCoy also will join Avon's board. Avon shares fell 2.9% premarket to $22.75 after jumping 21% last week in light of Coty's bid.

The 53-year-old McCoy has spent 30 years at Johnson & Johnson, most recently serving as a vice chairman on the company's executive committee, responsible for the company's consumer and pharmaceutical divisions. There, she oversaw consumer brands such as Neutrogena, Aveeno, Lubriderm, Clean & Clear and ROC.

McCoy's inexperience, however, in the direct-selling business and in the number of problems plaguing Avon also leave her a steep learning curve, Bernstein says, meaning that her turnaround plan may be a longer time coming than previously thought. Anything sooner might seem rushed or still bear the mark of Jung, whose credibility with investors is tarnished after recent miscues.

Until earlier this year, McCoy was believed to have an edge in getting the CEO post at Johnson & Johnson. She and Alex Gorsky were named to an executive committee in late 2010, creating a two-person succession race that McCoy ultimately lost. When Gorsky was named the next CEO in February, the company said McCoy would report to him when he assumes the post April 26.

Her performance in 2011 was praised by J&J's board, which cited accomplishments such as the pharma unit exceeding its sales and profit targets and the launch of several new products, according to J&J's proxy statement.

But her experience overseeing the consumer unit was more challenging. The board said that under McCoy's leadership, the McNeil over-the-counter medicine division made progress during 2011, fixing the problems that have led to a series of product recalls over the past two years. Recalls , though, continued during 2011 and into 2012. Overall, consumer unit sales were below target for 2011, though profits hit the mark.

McCoy had been with J&J since 1982, when she started as a research scientist. She rose within J&J's research division and then began leading various J&J franchises until taking over the pharma group in 2009. Her base salary was set at $932,400 for 2012. Overall compensation for 2011, including bonus and equity awards, was valued at $8.7 million.

-By Paul Ziobro, Dow Jones Newswires; 212-416-2194; [email protected]

--Nathalie Tadena contributed to this article.

Stocks mentioned in the article : Avon Products, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AVON PRODUCTS, INC.
10/05 AVON PRODUCTS : Majority of women do not know early signs of breast cancer, find..
10/05 AVON PRODUCTS : to Webcast Third-Quarter 2017 Earnings Conference Call
09/25 AVON PRODUCTS, INC. (NYSE : AVP) Files An 8-K Departure of Directors or Certain ..
09/25 AVON PRODUCTS INC : Change in Directors or Principal Officers (form 8-K)
09/25 AVON PRODUCTS : Majority of women do not know early signs of breast cancer, find..
09/06 BANK OF NEW YORK MELLON : Avon Products, Inc. (AVP) Shares Sold by Bank of New Y..
08/15 Global Cosmetic Products Market Is Projected to Grow at a CAGR over 5.4% Duri..
08/04 AVON PRODUCTS, INC. (NYSE : AVP) Files An 8-K Departure of Directors or Certain ..
08/04 AVON PRODUCTS INC : Change in Directors or Principal Officers, Financial Stateme..
08/03 AVON PRODUCTS, INC. (NYSE : AVP) reported earnings of ($0.03) per share missing ..
More news
News from SeekingAlpha
10/20 After Hours Gainers / Losers
10/17 Beauty names stumble after Nielsen data released
09/21 Consumer staples underperform after Dr Pepper warning
09/18 After Hours Gainers / Losers
08/23 MULTILEVEL MARKETING : Ethics And Business Model Persistently Heading Due South
Financials ($)
Sales 2017 5 775 M
EBIT 2017 370 M
Net income 2017 6,30 M
Debt 2017 1 238 M
Yield 2017 -
P/E ratio 2017 124,59
P/E ratio 2018 6,77
EV / Sales 2017 0,39x
EV / Sales 2018 0,37x
Capitalization 1 003 M
Chart AVON PRODUCTS, INC.
Duration : Period :
Avon Products, Inc. Technical Analysis Chart | AVP | US0543031027 | 4-Traders
Technical analysis trends AVON PRODUCTS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Average target price 3,45 $
Spread / Average Target 51%
EPS Revisions
Managers
NameTitle
Sherilyn S. McCoy Chief Executive Officer & Director
Chan W. Galbato Non-Executive Chairman
Jonathan Myers Chief Operating Officer & Executive Vice President
James Simpson Wilson Chief Financial Officer & Executive Vice President
Louise Scott Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
AVON PRODUCTS, INC.-55.16%1 003
PROCTER & GAMBLE COMPANY10.34%225 039
UNILEVER NV (ADR)49.51%165 458
UNILEVER (NL)33.58%164 522
UNILEVER38.15%164 522
COLGATE-PALMOLIVE COMPANY13.75%63 702